Roche in June bought out the rest of cancer genetics company Foundation Medicine that it didn't already own for $2.4 billion. It was the company's second cancer data-related acquisition of the year after Roche scooped up Flatiron Health for $1.9 billion. Roche Pharmaceuticals CEO Daniel O'Day told Business Insider why the company brought both of the companies directly under Roche in such quick succession. Swiss pharma giant Roche has been making big bets on cancer data. In June, it acquired the rest of cancer genetics company Foundation Medicine that it didn't already own for $2.4 billion.